Non-pharmacological therapies for postviral syndromes, including Long COVID: a systematic review and meta-analysis protocol.
Non-pharmacological therapies for postviral syndromes, including Long COVID: a systematic review and meta-analysis protocol.
复制标题
DOI：
10.1136/bmjopen-2021-057885
复制
发表时间：
2022-04-11
期刊：
影响因子：
2.9
通讯作者：
Haroon, Shamil
中科院分区：
文献类型：
--
作者：
Chandan, Joht Singh;Brown, Kirsty;Simms-Williams, Nikita;Camaradou, Jenny;Bashir, Nasir;Heining, Dominic;Aiyegbusi, Olalekan Lee;Turner, Grace;Cruz Rivera, Samantha;Hotham, Richard;Nirantharakumar, Krishnarajah;Sivan, Manoj;Khunti, Kamlesh;Raindi, Devan;Marwaha, Steven;Hughes, Sarah E.;McMullan, Christel;Calvert, Melanie;Haroon, Shamil
病毒后综合征（PVS）描述了急性病毒感染后持续数月甚至数年的症状。暴露于SARS-CoV-2病毒和随后的COVID-19发展已被证明具有类似的影响，个体持续表现出症状超过12周。持续存在的症状通常被称为“后COVID-19综合征”，“后COVID状况”或更常见的“长期COVID”。对长期COVID的长期健康影响和治疗方法的认识正在不断发展。为尽量减少与长期COVID治疗领域的现有工作重叠，我们仅选择专注于非药物治疗。本综述旨在总结PVS（包括长期COVID）非药物治疗的有效性。第二个目的是总结治疗研究招募的个体中与PVS相关的症状和健康影响。将在文献数据库中进行主要电子检索，包括：Embase、MEDLINE、PyscINFO、CINAHL和MedRxiv，检索时间为2001年1月1日至2021年10月29日。至少有两名独立的审查员将筛选每项研究，并将从所有合格的研究中提取数据，并将数据提取到数据提取表中。将使用科克伦偏倚风险工具和Newcastle-Ottawa分级系统评估所有纳入研究的质量。将对PVS和长期COVID的非药物治疗进行叙述性总结，并使用具有充分方法学同质性的随机效应荟萃分析汇总效应估计值。将提取纳入的非药物干预研究中报告的症状和健康影响，并进行叙述性报告。本系统性综述不需要伦理批准。这项研究的结果将提交同行评审出版物，在会议上分享，并传播给临床和患者群体。审查将遵循本方案，该方案也已在PROSPERO注册（CRD 42021282074）。
Postviral syndromes (PVS) describe the sustained presence of symptoms following an acute viral infection, for months or even years. Exposure to the SARS-CoV-2 virus and subsequent development of COVID-19 has shown to have similar effects with individuals continuing to exhibit symptoms for greater than 12 weeks. The sustained presence of symptoms is variably referred to as ‘post COVID-19 syndrome’, ‘post-COVID condition’ or more commonly ‘Long COVID’. Knowledge of the long-term health impacts and treatments for Long COVID are evolving. To minimise overlap with existing work in the field exploring treatments of Long COVID, we have only chosen to focus on non-pharmacological treatments. This review aims to summarise the effectiveness of non-pharmacological treatments for PVS, including Long COVID. A secondary aim is to summarise the symptoms and health impacts associated with PVS in individuals recruited to treatment studies. Primary electronic searches will be performed in bibliographic databases including: Embase, MEDLINE, PyscINFO, CINAHL and MedRxiv from 1 January 2001 to 29 October 2021. At least two independent reviewers will screen each study for inclusion and data will be extracted from all eligible studies onto a data extraction form. The quality of all included studies will be assessed using Cochrane risk of bias tools and the Newcastle-Ottawa grading system. Non-pharmacological treatments for PVS and Long COVID will be narratively summarised and effect estimates will be pooled using random effects meta-analysis where there is sufficient methodological homogeneity. The symptoms and health impacts reported in the included studies on non-pharmacological interventions will be extracted and narratively reported. This systematic review does not require ethical approval. The findings from this study will be submitted for peer-reviewed publication, shared at conference presentations and disseminated to both clinical and patient groups. The review will adhere to this protocol which has also been registered with PROSPERO (CRD42021282074).
登录
查看更多内容
影响因子：
17.3
作者：
Aiyegbusi OL;Hughes SE;Turner G;Rivera SC;McMullan C;Chandan JS;Haroon S;Price G;Davies EH;Nirantharakumar K;Sapey E;Calvert MJ;TLC Study Group
通讯作者：
TLC Study Group
影响因子：
9.6
作者：
Ong, KC;Ng, AWK;Earnest, A
通讯作者：
Earnest, A
影响因子：
2.8
作者：
Islam, Mohammed F.;Cotler, Joseph;Jason, Leonard A.
通讯作者：
Jason, Leonard A.
影响因子：
82.9
作者：
Blomberg B;Mohn KG;Brokstad KA;Zhou F;Linchausen DW;Hansen BA;Lartey S;Onyango TB;Kuwelker K;Sævik M;Bartsch H;Tøndel C;Kittang BR;Bergen COVID-19 Research Group;Cox RJ;Langeland N
通讯作者：
Langeland N
严重急性呼吸综合症对幸存者队列中肺功能，运动能力和生活质量的1年影响。
影响因子：
9.6
作者：
Hui DS;Wong KT;Ko FW;Tam LS;Chan DP;Woo J;Sung JJ
通讯作者：
Sung JJ